News

TargaZyme, Inc. Awarded SBIR Grant from National Eye Institute

TargaZyme, Inc. Awarded SBIR Grant from National Eye Institute

San Antonio, TX July 31, 2014 — TargaZyme, Inc. (formerly America Stem Cell, Inc.) a clinical- stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund its program for a novel cell-based restorative approach to treat diabetes- related retinopathy. This SBIR award is from the National Eye Institute and Targazyme will be collaborating with Dr. Maria Grant from the Department of Ophthalmology at Indiana University School of Medicine to conduct the research.

Retinal vascular […]

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

San Diego, CA  June 3, 2014  — TargaZyme, Inc. (formerly America Stem Cell, Inc. or the “Company”), a clinical-stage biopharmaceutical company developing enzyme platform technologies/products  to improve efficacy outcomes for cell therapy and cancer immunotherapy,  announced today that it has appointed Christopher Calhoun to its Business Advisory Board.

Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.

Lynnet Koh, Chairman & CEO of  TargaZyme, Inc., stated “Mr. Calhoun is a visionary entrepreuneur, a proven public company CEO with a successful track record with major […]

Targazyme, Inc. Appoints Dr. Mark W. Schwartz to Board of Directors

San Antonio, TX   March 4, 2014  — Targazyme, Inc. (formerly America Stem Cell, Inc., the “Company”) announced today that is has appointed Mark W. Schwartz, Ph.D. to the Company’s Board of Directors. Dr. Schwartz will serve the Company as an independent member of the Board.    As an independent director, Dr. Schwartz will assist in the Company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets.  With the appointment of […]

Targazyme, Inc. Selected to Present at 2014 BIO CEO & Investor Conference

San Antonio, TX   February 5, 2014  — Targazyme, Inc. (formerly America Stem Cell, Inc.) has been selected to present at the 2014 BIO CEO & Investor Conference being held in New York City on February 10-11, 2014.  The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Targazyme is a privately held clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy.  Targazyme will be presenting in the oncology track for private companies to some of the most influential […]

America Stem Cell, Inc. Changes Its Name to Targazyme, Inc.

Reports Interim Phase I/IIa Trial Results for TZ101, a Novel Enzyme Treatment to Enhance Stem Cell Targeting/Engraftment for Improved Cancer Patient Clinical Outcomes

SAN ANTONIO, TX DEC 18 2013.

America Stem Cell, Inc. (ASC) today announces that it has changed its name to Targazyme, Inc. (www.targazyme.com). The new name reflects the company’s family of enzyme products aimed at improving cell targeting and engraftment for better efficacy outcomes in stem cell and regenerative medicine.
Phase I/IIa results of Targazyme’s lead product, TZ101, were presented at the American Society of Hematology meeting in New Orleans (Popat et al. Abstract #691, Dec 9). The Phase […]

America Stem Cell, Inc. Announces Presentation of Clinical Data at Upcoming American Society of Hematology (ASH) Meeting

SAN ANTONIO TX DEC 4, 2013.
America Stem Cell, Inc. (ASC) today announced that three presentations will be made at the upcoming American Society of Hematology (ASH) meeting in New Orleans, LA December 7-10, 2013 on its lead product, ASC-101. ASC-101 is currently undergoing evaluation in a dual umbilical cord blood transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome at The University of Texas MD Anderson Cancer Center. To date, 16 patients have been transplanted with cord blood that was treated with ASC-101 immediately prior to transplant. On the basis of interim data, ASC received clearance from the U.S. Food and Drug Administration […]

America Stem Cell, Inc to Present at 12th Annual BIO Investor Forum. BIO Investor Forum to be held October 8-9 in San Francisco, Calif.

San Francisco, CA, October 1, 2013 – America Stem Cell, Inc (ASC) announced that Lynnet Koh, CEO will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif.

“ASC was founded with the vision to make stem cell transplantation and cell therapy safer and more efficacious for patients. The profound efficacy and safety results from our current Phase I/IIa trial at M.D. Anderson Cancer Center with […]

Circulating Mononuclear Progenitor Cells: Differential Roles for Subpopulations in Repair of Retinal Vascular Injury

Caballero S, Hazra S, Bhatwadekar A, Li Calzi S, Paradisio LJ, Miller LP, Chang L., Kern TS and Grant MB. Circulating Mononuclear Progenitor Cells: Differential Roles for Sub-populations in Repair of Retinal Vascular Injury. Invest Ophthalmol Vis Sci. 2013 Apr 26;54(4):3000-9. doi: 10.1167/iovs.12-10280.

America Stem Cell, Inc. Awarded A Phase I SBIR To Explore The Therapeutic Potential Of Its Platform Technology (ASC-101) With Neural Stem Cells In Multiple Sclerosis Model

SAN ANTONIO, TX JANUARY 7, 2013.

America Stem Cell, Inc (ASC) today announced that it has been awarded an Advanced Technology Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be led by Dr. Leonard Miller, VP Preclinical Research at ASC, in collaboration with Dr. Larry Sherman at the Oregon National Primate Research Center, Oregon Health & Science University (OHSU). Dr. Sherman’s lab has over 15 years of extensive experience in multiple models of demyelinating diseases such as multiple sclerosis (MS), and in the application of […]

America Stem Cell, Inc. Awarded a Phase I STTR To Explore The Therapeutic Potential Of Its Platform Technology (ASC-101) With Amniotic Fluid-Derived Stem Cells

SAN ANTONIO, TX SEPTEMBER 17, 2012.

America Stem Cell, Inc (ASC) today announced that it has been awarded an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be conducted in collaboration with scientists at the Wake Forest Institute of Regenerative Medicine (WFIRM) in Winston-Salem, NC, and will explore the combination of two technologies: ASC-101 developed by America Stem Cell and amniotic fluid-derived stem cells discovered and pioneered by Dr. Shay Soker and colleagues at WFIRM. We will examine the […]